公开(公告)号：US20160008463A1

公开(公告)日：2016-01-14

申请号：US14850794

申请日：2015-09-10

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD

Inventor： Michal EISENBACH-SCHWARTZ ,  Kuti BARUCH ,  Neta ROSENZWEIG

IPC: A61K39/395 ,  A61K39/00

CPC classification number: C07K16/2803 ,  A61K31/404 ,  A61K31/4155 ,  A61K31/7068 ,  A61K33/36 ,  A61K38/00 ,  A61K38/005 ,  A61K38/02 ,  A61K38/14 ,  A61K38/168 ,  A61K38/18 ,  A61K38/208 ,  A61K39/395 ,  A61K39/39541 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2121/00 ,  C07K16/2818 ,  C07K16/2827 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/75 ,  C07K2317/76 ,  A61K2300/00

Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.

Abstract translation: 一种包含活性剂的药物组合物，其引起个体中用于治疗不包括自身免疫性神经炎症性疾病，复发性多发性硬化症（RRMS）的疾病，病症，病状或损伤的个体的全身免疫抑制水平的降低 ）。 药物组合物用于通过包含至少两个治疗疗程的剂量方案给药，每个治疗过程依次包括治疗会话，随后是间歇疗程的非治疗。

公开(公告)号：US20160213762A1

公开(公告)日：2016-07-28

申请号：US15095300

申请日：2016-04-11

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： Michal EISENBACH-SCHWARTZ ,  Jonathan KIPNIS

IPC: A61K39/00 ,  A61K39/39

CPC classification number: A61K39/0005 ,  A61K39/0007 ,  A61K39/39

Abstract: Copolymer 1, a Copolymer 1-related peptide, a Copolymer 1-related polypeptide, and T cells activated therewith are useful in methods and compositions for treatment of psychiatric disorders, diseases and conditions.

Abstract translation: 共聚物1，共聚物1相关肽，共聚物1相关多肽和活化的T细胞可用于治疗精神疾病，疾病和病症的方法和组合物。

公开(公告)号：US20160166612A1

公开(公告)日：2016-06-16

申请号：US14898732

申请日：2014-05-22

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD

Inventor： Michal EISENBACH-SCHWARTZ ,  Ester YOLES ,  Inbal BENHAR BAR-ON

IPC: A61K35/15 ,  A61K9/00

CPC classification number: A61K35/15 ,  A61K9/0048 ,  A61K35/17 ,  A61K39/0008 ,  A61K2035/122 ,  A61K2039/5154 ,  C12N5/0645

Abstract: A monocyte subpopulation having a low relative amount, or substantially devoid, of CD3+ cells, CD19+ cells, CD56+ cells and optionally CD16+ cells is provided, wherein the monocyte subpopulation is for use in inhibition of neuronal degeneration, protection of neurons from glutamate toxicity or promotion of nerve regeneration in the retina or optic nerve, wherein the retina or optic nerve is damaged by a disease, disorder or condition of the eye, or for treatment of an inflammatory disease, disorder or condition of the eye.

Abstract translation: 提供了具有低相对量或基本上不含CD3 +细胞，CD19 +细胞，CD56 +细胞和任选的CD16 +细胞的单核细胞亚群，其中所述单核细胞亚群用于抑制神经元变性，保护神经元免于谷氨酸毒性或促进 在视网膜或视神经中的神经再生，其中视网膜或视神经被眼睛的疾病，病症或状况损伤，或用于治疗眼睛的炎性疾病，病症或病症。

公开(公告)号：US20140134196A1

公开(公告)日：2014-05-15

申请号：US14162482

申请日：2014-01-23

Applicant: Yeda Research and Development Co., Ltd.

Inventor： Michal EISENBACH-SCHWARTZ ,  Ester YOLES ,  Oleg BUTOVSKY ,  Jonathan KIPNIS

IPC: A61K39/00

CPC classification number: A61K39/0007 ,  A61K39/00 ,  A61K39/0008 ,  A61K2039/5158

Abstract: Methods and compositions are provided for treatment of neurodegenerative diseases in which there is accumulation of misfolded and/or aggregated proteins, excluding prion diseases. In particular, the invention relates to treatment of the neurodegenerative diseases Huntington's disease (HD), Alzheimer's disease (AD) or Parkinson's disease (PD), by administration of an agent selected from the group consisting of (i) Copolymer 1, (ii) a Copolymer 1-related peptide, (iii) a Copolymer 1-related polypeptide, and (iv) T cells activated with (i), (ii) or (iii).

Abstract translation: 提供方法和组合物用于治疗除了朊病毒疾病之外存在错误折叠和/或聚集蛋白质积累的神经变性疾病。 特别地，本发明涉及治疗神经退行性疾病亨廷顿病（HD），阿尔茨海默病（AD）或帕金森病（PD）），通过施用选自（i）共聚物1，（ii） 共聚物1相关肽，（iii）共聚物1相关多肽，和（iv）用（i），（ii）或（iii）活化的T细胞。

公开(公告)号：US20180207249A1

公开(公告)日：2018-07-26

申请号：US15856863

申请日：2017-12-28

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： Michal EISENBACH-SCHWARTZ ,  Jonathan KIPNIS

IPC: A61K39/00 ,  A61K39/39

CPC classification number: A61K39/0005 ,  A61K39/0007 ,  A61K39/39

Abstract: Copolymer 1, a Copolymer 1-related peptide, a Copolymer 1-related polypeptide; and T cells activated therewith are useful in methods and compositions for treatment of psychiatric disorders, diseases and conditions.

公开(公告)号：US20160000909A1

公开(公告)日：2016-01-07

申请号：US14797894

申请日：2015-07-13

Applicant: Yeda Research and Development Co. Ltd

Inventor： Michal EISENBACH-SCHWARTZ ,  Kuti BARUCH ,  Neta ROSENZWEIG

IPC: A61K39/395 ,  A61K31/4155 ,  C07K16/28

CPC classification number: C07K16/2803 ,  A61K31/404 ,  A61K31/4155 ,  A61K31/7068 ,  A61K33/36 ,  A61K38/00 ,  A61K38/005 ,  A61K38/02 ,  A61K38/14 ,  A61K38/168 ,  A61K38/18 ,  A61K38/208 ,  A61K39/395 ,  A61K39/39541 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2121/00 ,  C07K16/2818 ,  C07K16/2827 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/75 ,  C07K2317/76 ,  A61K2300/00

Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.

Abstract translation: 一种包含活性剂的药物组合物，其引起个体中用于治疗不包括自身免疫性神经炎症性疾病，复发性多发性硬化症（RRMS）的疾病，病症，病状或损伤的个体的全身免疫抑制水平的降低 ）。 药物组合物用于通过包含至少两个治疗疗程的剂量方案给药，每个治疗过程依次包括治疗会话，随后是间隔期。

公开(公告)号：US20150209404A1

公开(公告)日：2015-07-30

申请号：US14677123

申请日：2015-04-02

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： Michal EISENBACH-SCHWARTZ ,  Ester YOLES ,  Hadas SCHORI

IPC: A61K38/07 ,  G01N33/569 ,  A61K31/4985 ,  A61K31/53 ,  A61K31/7068 ,  A61K31/519

CPC classification number: A61K38/07 ,  A61K31/00 ,  A61K31/4985 ,  A61K31/519 ,  A61K31/53 ,  A61K31/7068 ,  A61K35/15 ,  A61K45/00 ,  A61K45/06 ,  G01N33/56972 ,  G01N33/6896 ,  G01N2333/70553 ,  G01N2333/70596 ,  G01N2800/28 ,  G01N2800/50 ,  G01N2800/52

Abstract: The present invention provides methods for early diagnosis of amyotrophic lateral sclerosis (ALS) and for determining the efficacy of a treatment for ALS in an ALS patient, i.e., monitoring ALS progression, utilizing cellular blood markers; as well as kits for carrying out these methods.

Abstract translation: 本发明提供了用于早期诊断肌萎缩性侧索硬化（ALS）并用于确定ALS患者中ALS治疗的功效的方法，即利用细胞血液标志物监测ALS进展; 以及执行这些方法的工具包。